Related Experiment Video
Updated: Aug 14, 2026
Assessment of the Acute Inhalation Toxicity of Airborne Particles by Exposing Cultivated Human Lung Cells at the Air-Liquid Interface
Published on: February 23, 2020
Methods to assess potential reduced exposure products
Dorothy K Hatsukami1, Gary A Giovino, Thomas Eissenberg
1University of Minnesota Cancer Center, Minneapolis, MN 55414, USA. hatsu001@umn.edu
Abstract:
The availability of tobacco products purported to reduce toxin exposure or potentially reduce health risks necessitates the development of methods and identification of biomarkers that can be used to assess these products. These assessments occur on multiple levels and stages, from identifying constituents in the tobacco products and smoke, to human exposure and health effects trials, to postmarketing surveillance. A conference of multidisciplinary experts was convened to present and discuss methods and biomarkers to assess these products and to consider the infrastructure necessary to facilitate the evaluation process. Although no currently available set of measures was thought to be sufficient for determining the relative health risk of potential reduced exposure products, this paper provides a blueprint for future research toward this end.
Insights
Assessing reduced exposure tobacco products requires new methods and biomarkers. While current measures are insufficient, this paper outlines a research blueprint for evaluating these products and their potential health risks.
Area of Science:
- Tobacco regulatory science
- Biomarker discovery
- Toxicology
Background:
- Emerging tobacco products claim reduced toxin exposure or health risks.
- Assessing these claims requires robust scientific evaluation methods.
- Current assessment strategies are multi-staged, from product analysis to human trials.
Purpose of the Study:
- To convene multidisciplinary experts to discuss methods and biomarkers for assessing novel tobacco products.
- To identify necessary infrastructure for facilitating product evaluation.
- To address the need for reliable methods to determine relative health risks of reduced exposure products.
Main Methods:
- Expert conference to present and discuss assessment methodologies.
- Review of existing and proposed biomarkers for exposure and health effects.
- Consideration of infrastructure requirements for comprehensive evaluation.
Main Results:
- No single set of current measures is sufficient for determining relative health risks.
- A need exists for further development of assessment methods and biomarkers.
- Expert consensus highlighted the complexity of evaluating reduced exposure products.
Conclusions:
- A comprehensive blueprint for future research is provided.
- Further development of methods and biomarkers is crucial for accurate product assessment.
- Continued multidisciplinary collaboration is essential for advancing tobacco regulatory science.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:23Toxicity Testing in Animals